About us
We put the patient and their family at the center. We believe that clear, accessible, and evidence-based information allows for better decision-making throughout the process.
Lung cancer today is not the same as it was 5, 10 or 20 years ago.
The patient and his family, in the center.
Everything we do is based on their real needs.
Clear, evidence-based information.
Reliable, up-to-date, and simple content.
Science and community, connected.
We build bridges between professionals, patients, and families through empathy .
We do not replace medical consultation, we do not give personalized treatment instructions, we do not promote therapies, we do not address topics without scientific references, we do not use fear as a tool.
Navigating the diagnostics
A diagnosis generates doubts, fear, and a sense of urgency. Getting information step by step helps you organize your decisions and understand what comes next.
Small cell lung cancer (SCLC)
Less frequent and with a different progression. Requires specific strategies from the outset. Currently, many new therapies are under development.
Non-small cell lung cancer (NSCLC)
It is the most common type, and today there are multiple treatments depending on its characteristics. The most common type of non-small cell lung cancer (NSCLC) is adenocarcinoma.
Build your team
Forming a comprehensive team is essential to support symptoms, make decisions, and feel cared for.
Oncologist
The oncologist coordinates the diagnosis, studies, and treatment.
He is the one who integrates clinical, molecular, and imaging information to define the best options at each stage.
Types of studies
Imaging studies
CT scans, PET scans, and MRI allow for the evaluation of disease extent and the measurement of response.
Biopsy
It confirms the diagnosis and allows for precise treatment of the tumor.
%205_49_48%E2%80%AFp_%C2%A0m_.png)
Molecular Profile
They are looking for tumor biomarkers that guide treatment options.
Biomarkers
These are tumor alterations that can change treatment options. Identifying them before deciding on therapies is crucial because they guide which treatments are most likely to work. They are usually found in the biopsy report, and it's important to request that they be analyzed.
Lung cancer is not a single disease: it is a group of distinct diseases, defined by these molecular characteristics.
PDL-1
Marker that guides the use of immunotherapy as a single treatment or in combination with chemotherapy.
ROS1
theros1ders.org
Similar to ALK. Allows for specific therapies.
PDL-1
Marker that guides the use of immunotherapy as a single treatment or in combination with chemotherapy.
Biomarkers
These are tumor alterations that can change treatment options. Identifying them before deciding on therapies is crucial because they guide which treatments are most likely to work. They are usually found in the biopsy report, and it's important to request that they be analyzed.
Lung cancer is not a single disease: it is a group of distinct diseases, defined by these molecular characteristics.
